Abstract 1678P
Background
Breast cancer have a significant impact on the life of married couples. Partners are faced with many challenges such as the heavy treatments and the body changes associated with the disease.
Methods
We conducted a study including patients treated for breast cancer in Salah Azaiz Institute. The aim was to evaluate the impact of cancer on the couple's relationship. The patients agreed to answer a marital adjustment questionnaire (MAQ).
Results
The study included 53 patients with a mean age of 52.25 years, ranging from 34 to 72 years. At the time of the study, 83% (n=44) had been married for between 3 and 60 years, with a mean of 22.5 years and a standard deviation of 11.4. The age at marriage was 27.80±6.9 years, with extremes ranging from 15 to 50 years. Fifteen per cent of patients had no children, and the number of children ranged from 1 to 5, with an average of 2.2. The average age difference between the married women and their partners was 5.3 years, with extremes ranging from one year to 23 years. More than half of the population studied in couple had intimacy problems (n=34),. The mean marital agreement score was 81.65 [41-120]. Eight couples no longer engaged in activities together outside the home and 39.5% (n=21) of them very little. Twenty-nine patients (54.7%) said that they almost never showed affection to their partners. The study of sexual activity showed an abstinence rate of 35.8% (n=19) compared to versus 0% before cancer. A quarter of our population had less than two sexual encounters per month after the disease, compared with 20.8% (n=11) and only 10% had more than 4 intercourses per month compared with 50.9% (n=27), before treatment. Twenty patients (37.3%) frequently disagreed about the sexual relationship. Fifty-four per cent (n=29) of the patients interviewed stated that they had a sexual complaint at the time of the survey: Among them, 32% (n=17) had spoken to their partners about the subject. Twenty-two (n=12) of the patients said they could no longer confide in their partner.
Conclusions
Breast cancer requires adjustments in married life, but with mutual support and open communication, couples can overcome these challenges together.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11